{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:10:03Z","timestamp":1789398603269,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Striking number of mutations found in the spike protein of recently emerged SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.3 and BA.4\/5 has raised serious concerns regarding the escape from current antibody therapies and vaccine protection. Here, we conducted comprehensive analysis on the extent of two major Omicron lineages BA.1\/BA.1.1 and BA.2 to escape neutralization from the therapeutic antibodies approved by the regulatory authorities and convalescent plasma from SARS-CoV-2 patients infected during initial wave of pandemic in early 2020. We showed that Omicron BA.1\/BA.1.1 were the most resistant in both magnitude and breadth against antibodies and convalescent plasma, followed by Beta, BA.2, Gamma, Delta and Alpha. While the majority of therapeutic antibodies lost binding and neutralization to Omicron variants, BRII combo (BRII-196 + BRII-198), S309, and AZ combo (COV2-2196 + COV2-2130) maintained neutralization despite of reduction due to either conserved epitope or combinational effect between the two designated antibodies. A single intraperitoneal injection of BRII combo as a prophylactic treatment protected animals from Omicron infection. Treated animals manifested normal body weight, survived infection up to 14 days, undetectable levels of infectious viruses in the lungs, and reduced lung pathology compared to the controls. Analyzing ACE2 from diverse host species showed that Omicron variants acquired ability to use mouse ACE2 for entry. These results demonstrate major antigenic shifts and potentially broadening the host range of two major Omicron lineages BA.1\/BA.1.1 and BA.2, posing serious challenges to current antibody therapies and vaccine protection as well as increasing danger of spillover into the wildlife.<\/jats:p>","DOI":"10.3389\/fimmu.2022.854952","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:32:06Z","timestamp":1655440326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2"],"prefix":"10.3389","volume":"13","author":[{"given":"Ruoke","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Qin","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Hao","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Jang Hann","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.immuni.2021.06.003","article-title":"Analysis of SARS-CoV-2 Variant Mutations Reveals Neutralization Escape Mechanisms and the Ability to Use ACE2 Receptors From Additional Species","volume":"54","author":"Wang","year":"2021","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04085-y","article-title":"Impact of Circulating SARS-CoV-2 Variants on mRNA Vaccine-Induced Immunity","volume":"600","author":"Lucas","year":"2021","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh2315","article-title":"Defining Variant-Resistant Epitopes Targeted by SARS-CoV-2 Antibodies: A Global Consortium Study","volume":"374","author":"Hastie","year":"2021","journal-title":"Sci (New York N.Y.)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced Neutralization of SARS-CoV-2 B.1.617 by Vaccine and Convalescent Serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.372.6549.1375","article-title":"Delta Variant Triggers New Phase in the Pandemic","volume":"372","author":"Kupferschmidt","year":"2021","journal-title":"Sci (New York N.Y.)"},{"key":"B7","unstructured":"SARS-CoV-2 Lineages: B.1.617.2 Report2021"},{"key":"B8","unstructured":"Tracking SARS-CoV-2 Variants2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04188-6","article-title":"The Emergence, Genomic Diversity and Global Spread of SARS-CoV-2","volume":"600","author":"Li","year":"2021","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.03.21268582","article-title":"Mapping the Antigenic Diversification of SARS-CoV-2","author":"van der Straten","year":"2022"},{"key":"B11","unstructured":"SARS-CoV-2 Variants of Concern and Variants Under Investigation in England: Technical Briefing 142021"},{"key":"B12","unstructured":"Science Brief: Omicron (B.1.1.529) Variant2021"},{"key":"B13","unstructured":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern2021"},{"key":"B14","volume-title":"Statement on Omicron Sublineage BA.2","year":"2022"},{"key":"B15","doi-asserted-by":"publisher","first-page":"494\u20136","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 Vaccine Against Omicron Variant in South Africa","volume":"386","author":"Collie","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00090-3","article-title":"Breakthrough Infections With SARS-CoV-2 Omicron Despite mRNA Vaccine Booster Dose","volume":"399","author":"Kuhlmann","year":"2022","journal-title":"Lancet (London England)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.14.480335","article-title":"Virological Characteristics of SARS-CoV-2 BA.2 Variant","volume":"2022","author":"Yamasoba","year":"2022","journal-title":"bioRxiv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"664\u201370","DOI":"10.1038\/d41586-021-03825-4","article-title":"Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift","volume":"602","author":"Cameroni","year":"2021","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1111\u201321","DOI":"10.1016\/j.jgg.2021.12.003","article-title":"Evidence for a Mouse Origin of the SARS-CoV-2 Omicron Variant","volume":"48","author":"Wei","year":"2021","journal-title":"J Genet Genomics = Yi Chuan xue bao"},{"key":"B20","doi-asserted-by":"publisher","first-page":"676\u201381","DOI":"10.1038\/d41586-021-03826-3","article-title":"Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"447\u201356","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron Variant Is Highly Resistant Against Antibody-Mediated Neutralization \u2013 Implications for Control of the COVID-19 Pandemic","volume":"185","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"467\u2013484","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 Leads to Widespread Escape From Neutralizing Antibody Responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"671\u201375","DOI":"10.1038\/d41586-021-03827-2","article-title":"Considerable Escape of SARS-CoV-2 Omicron to Antibody Neutralization","volume":"602","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"657\u201363","DOI":"10.1038\/d41586-021-03796-6","article-title":"Omicron Escapes the Majority of Existing SARS-CoV-2 Neutralizing Antibodies","volume":"602","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"553\u20136","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.15.480166","article-title":"Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies","author":"Zhou","year":"2022","journal-title":"bioRxiv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.30.442182","article-title":"LY-CoV1404 (Bebtelovimab) Potently Neutralizes SARS-CoV-2 Variants","author":"Westendorf","year":"2022","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"654\u20136","DOI":"10.1038\/d41586-021-03824-5","article-title":"Omicron Extensively But Incompletely Escapes Pfizer BNT162b2 Neutralization","volume":"602","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.21267755","article-title":"mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant","author":"Garcia-Beltran","year":"2021","journal-title":"medRxiv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"234\u20136","DOI":"10.1016\/s0140-6736(21)02844-0","article-title":"Reduced Neutralisation of SARS-CoV-2 Omicron B.1.1.529 Variant by Post-Immunisation Serum","volume":"399","author":"Dejnirattisai","year":"2021","journal-title":"Lancet (London England)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.15.484542","article-title":"Omicron BA.1 and BA.2 Neutralizing Activity Elicited by a Comprehensive Panel of Human Vaccines","author":"Bowen","year":"2022","journal-title":"bioRxiv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1579\u201380","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"Yu","year":"2022","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","article-title":"Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization","volume":"29","author":"Wang","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 Variants B.1.351 and P.1 Escape From Neutralizing Antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y","article-title":"In Vivo Monoclonal Antibody Efficacy Against SARS-CoV-2 Variant Strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00772-y","article-title":"Delta Variant (B.1.617.2) Sublineages do Not Show Increased Neutralization Resistance","volume":"18","author":"Arora","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03925-1","article-title":"Lectins Enhance SARS-CoV-2 Infection and Influence Neutralizing Antibodies","volume":"598","author":"Lempp","year":"2021","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.766821","article-title":"A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants","volume":"12","author":"Shan","year":"2021","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(21)00068-9","article-title":"SARS-CoV-2 Spike E484K Mutation Reduces Antibody Neutralisation","volume":"2","author":"Jangra","year":"2021","journal-title":"Lancet Microbe"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","article-title":"SARS-CoV-2 501y.V2 Variants Lack Higher Infectivity But Do Have Immune Escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1139","article-title":"Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants","volume":"373","author":"Yuan","year":"2021","journal-title":"Sci (New York N.Y.)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe5901","article-title":"Transmission of SARS-CoV-2 on Mink Farms Between Humans and Mink and Back to Humans","volume":"371","author":"Oude Munnink","year":"2021","journal-title":"Sci (New York N.Y.)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"481\u20136","DOI":"10.1038\/s41586-021-04353-x","article-title":"SARS-CoV-2 Infection in Free-Ranging White-Tailed Deer","volume":"602","author":"Hale","year":"2021","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00326-9","article-title":"Transmission of SARS-CoV-2 Delta Variant (AY.127) From Pet Hamsters to Humans, Leading to Onward Human-to-Human Transmission: A Case Study","volume":"399","author":"Yen","year":"2022","journal-title":"Lancet (London England)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1038\/s41467-021-25903-x","article-title":"Characterization and Structural Basis of a Lethal Mouse-Adapted SARS-CoV-2","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.19.21249592","article-title":"The N501Y Mutation in SARS-CoV-2 Spike Leads to Morbidity in Obese and Aged Mice and Is Neutralized by Convalescent and Post-Vaccination Human Sera","author":"Rathnasinghe","year":"2021","journal-title":"medRxiv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c Mice for Testing Vaccine Efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Sci (New York N.Y.)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn8652","article-title":"Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement","volume":"375","author":"McCallum","year":"2022","journal-title":"Sci (New York N.Y.)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01678-y","article-title":"An Infectious SARS-CoV-2 B.1.1.529 Omicron Virus Escapes Neutralization by Therapeutic Monoclonal Antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently Neutralizing and Protective Human Antibodies Against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2381-y","article-title":"A Human Neutralizing Antibody Targets the Receptor-Binding Site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0827","article-title":"Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Sci (New York N.Y.)"},{"key":"B57","doi-asserted-by":"publisher","first-page":":e2025373118","DOI":"10.1073\/pnas.2025373118","article-title":"Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41467-020-20501-9","article-title":"Antibody Neutralization of SARS-CoV-2 Through ACE2 Receptor Mimicry","volume":"12","author":"Ge","year":"2021","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.854952\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:32:15Z","timestamp":1655440335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.854952\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2022.854952"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.854952","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"article-number":"854952"}}